- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05692258
Acupuncture as an Adjunctive Therapy for Covid-19 Omicron Randomised Controlled Trial in Patients With Moderate/Severe Pneumonia (ZCFZZLXGBDFYHZ)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a stratified randomized trial. Firstly, the subjects were stratified according to disease severity (moderate, severe) and age stage (30-59 years, > 60 years), and then the subjects were randomly assigned to the observation group and the control group within each stratum. The study center will screen cases strictly according to the diagnostic criteria, inclusion criteria and exclusion criteria. After confirmation of enrollment, random numbers will be obtained according to the application for random coding process until the total number of observation is completed. Blinded evaluation will be adopted in the trial, and the third party who does not know the grouping will evaluate the efficacy. Blind statistical analysis was used in the data summary stage, and the researchers, operators and statisticians were separated. In the observation group (acupuncture treatment + basic treatment), acupuncture will be applied at Dazhui (GV 14), Feishu (BL 13), Dingchuan (GV 14), Tiantu (GV 14), Danzhong (CV 17), Quchi (GV 20), Gongzhi (CV 4), Neiguan (PC 6), Yinlingquan (SP 9), Fenglong (ST 40), Qihai (CV 6). In the control group (sham acupuncture + basic treatment), sham acupuncture will be used. The acupoint selection is the same as the acupuncture treatment group, Before acupuncture, the fixed pad was pasted on the acupoints, 1.5-inch blunt needle will be used to Pierce the skin surface through the fixed pad of the sham appliance without puncturing the skin.
The mMRC and COVID-19 symptom assessment scale were used as the main evaluation indicators, and the Leicester cough questionnaire LCQ was used to record cough. VAS pain score visual analogue scale was used to evaluate the daily situation of sore throat, muscle soreness, and headache. Secondary outcomes included vital signs and oxygen saturation, chest CT score, and related blood biochemical indicators, including: Blood routine, coagulation routine, D-dimer, C-reactive protein, erythrocyte sedimentation rate, procalcitonin, cytokines (interleukin-6, interleukin-1, ferritin), myocardial enzymes, T lymphocyte subsets (CD4+, CD8+), liver function, renal function, blood gas analysis (severe patients), nucleic acid negative conversion rate, severe conversion rate, self-rating anxiety scale (SAS). Uniform training was provided to all study personnel. The training focused on the use of randomization system and case entry system, project implementation and standard operating procedures, so that each researcher could be familiar with the research process and specific implementation rules, so as to improve the intra-observer consistency and inter-observer consistency of researchers and ensure the reliability of clinical research conclusions. An independent efficacy evaluator was required. Efficacy raters and statistical analysts were blinded. Statistical analyses were performed by a third party, and statistical analysts were blinded during the trial. Statistical analysis will be calculated using SPSS22.0 statistical analysis software. P<0.05 (i.e., =0.05) was considered to indicate statistical significance.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wei Zhang, Doctor
- Phone Number: 0731 +8613548639198
- Email: 507395550@qq.com
Study Contact Backup
- Name: Wenying Shi, Master
- Phone Number: 0731 +8613875866937
- Email: 273727875@qq.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410001
- Recruiting
- The First Affiliated Hospital of Hunan University of Chinese Medicine
-
Contact:
- Wei Zhang, Doctor
- Phone Number: 0731 +86 135 4863 9198
- Email: 507395550@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- (1) in accordance with the diagnostic criteria of western medicine. (2) moderate and severe clinical types; (3) patients over 30 years old. (4) Patients voluntarily participated in the study and signed the informed consent.
Exclusion Criteria:
- (1) critical COVID-19 patients; (2) Allergic constitution, allergic to traditional Chinese medicine components; (3) pregnant or lactating women; (4) complicated with severe cognitive and mental disorders that cannot be clearly expressed; (5) those participating in other clinical trials; (6) According to the investigator's judgment, there will be patients with complicated enrollment or poor compliance, which will affect the efficacy and safety evaluation.
(7) complicated with active pulmonary tuberculosis, malignant arrhythmia, acute myocardial infarction, acute stroke, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acupuncture therapy + basic therapy
Acupuncture treatment-Selected acupoints: Dazhui (GV14) , Feishu(BL13), Dingchuan(EX-B1), Tiantu(CV22), Danzhong(RN17), Quchi(LI11), Kongzui(LU6), Neiguan(PC6), Yinlingquan(SP9), Fenglong(ST40), Qihai(cv6). Once a day for 10 consecutive times. Western medicine treatment (basic treatment) : According to the Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial 10th Edition) issued by the General Office of the National Health Commission and the General Department of the National Administration of Traditional Chinese Medicine, patients are arranged to be quarantined in hospitals for treatment. Conventional Western medicine treatment includes supportive treatment, antiviral therapy, immunotherapy, anticoagulant therapy, antibiotic therapy, etc. |
Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint). Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.
Other Names:
|
Sham Comparator: sham acupuncture + basic therapy
sham acupuncture.
Acupoint selection, body position, intervention time and course of treatment are the same as those in acupuncture treatment group.
After acupoint disinfection, fixed pad is pasted on the acupoint, and 1.5 blunt needle will be used to Pierce directly through the sham instrument to fix pad to the skin surface without piercing the skin, and do not require Deqi.
Western medicine treatment (basic treatment) is the same as the acupuncture group.
|
Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint). Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Medical Research Council Dyspnea Scale
Time Frame: Once a day
|
On a scale of 0-4, the higher the score, the more severe the symptoms
|
Once a day
|
Symptom Assessment Scale for novel coronavirus pneumonia
Time Frame: Evaluate once a day
|
15 items: 7 main symptoms (0-3 points), 8 secondary symptoms (0-1 points), the higher the score, the more severe the symptoms
|
Evaluate once a day
|
Leicester cough questionnaire
Time Frame: During the screening period and on the 10th day of treatment
|
19 items, divided into physiological, pathological and social dimensions, each item scored 1-7 points.
Dimension score = Total score of item questions in each dimension ➗ Number of questions (1-7).Total score = Sum of three dimensions scores (3-21)
|
During the screening period and on the 10th day of treatment
|
Visual Analogue Scale/Scor
Time Frame: Evaluate once a day
|
3 items: pharyngeal pain, muscle soreness, headache.
Pain is divided into 10 points, 0 points means no pain, 10 points means severe pain, the middle part of the different degrees of pain.
Have the patient draw a mark on the horizontal line according to how they feel, which indicates the level of pain.
The higher the score, the worse the pain.
|
Evaluate once a day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vital signs and oxygen saturation
Time Frame: Record twice daily
|
Body temperature, pulse, respiration, blood pressure, oxygen saturation
|
Record twice daily
|
Chest CT score
Time Frame: Screening period, the 10th day of treatment
|
In 6 areas of the right lung upper field, right lung middle field, right lung lower field, left lung upper field, left lung middle field, left lung lower field, reticular change 1 point, ground glass 2 points, patchy blur 3 points, small patchy blur 4 points, cystic lung honeycomb 5 points, the total score is 30 points, the higher the score is, the more severe the lung lesions.
|
Screening period, the 10th day of treatment
|
Related blood biochemical indicators
Time Frame: Screening period, treatment days 3, 7, and 10.
|
Routine blood test, coagulation test, D-dimer, C-reactive protein, erythrocyte sedimentation rate, procalcitonin, cytokines (interleukin-6, interleukin-1, ferritin), myocardial enzymes, T lymphocyte subsets (CD4+, CD8+), liver function, renal function laboratory indicators, and blood gas analysis were also recorded in severe patients.
|
Screening period, treatment days 3, 7, and 10.
|
Negative conversion rate of nucleic acid
Time Frame: Screening period, treatment days 3, 7, and 10.
|
The nucleic acid of 2019-ncov will be detected by fluorescence quantitative polymerase chain reaction, and the negative conversion rate of nucleic acid will be calculated
|
Screening period, treatment days 3, 7, and 10.
|
Conversion rate of severe disease
Time Frame: Tenth day of treatment
|
According to the clinical classification of "Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10th Edition)", the number of patients who turned from medium to severe or critical will be recorded.
Calculate the conversion rate of severe disease (number of severe disease cases/total cases × 100%)
|
Tenth day of treatment
|
The total score of the self-rating anxiety Scale
Time Frame: Screening period, treatment days 3, 7, and 10
|
20 items, each item 1-4 points, total score and standard score (total score ×1.25), the higher the score, the more severe symptoms.
|
Screening period, treatment days 3, 7, and 10
|
Collaborators and Investigators
Investigators
- Study Chair: Wei Zhang, Doctor, +86 135 4863 9198
Publications and helpful links
Helpful Links
- Chen Wen-tao, Fu Huai-li, ZHANG Chao-yuan, et al. Feasibility Analysis of Acupuncture and Moxibustion in the Prevention and Treatment of COVID-19 from an International Perspective. Clinical Journal of Acupuncture and Moxibustion, 2020, 36(9): 82-87.
- Gong Yabin, Shi Xin-jie, Zhang Yan, et al. Clinical application and practice ofacupuncture therapy in treatment of coronavirus disease 2019. Chinese Acupuncture and Moxibustion, 2021, 41(2): 142-144.
- Yin Xin, CAI Shubin, Chen Luming, et al. Seventeen cases with coronavirus disease 2019(COVID-19)treated with the combination of acupuncture and herbal medicine. Chinese Acupuncture and Moxibustion, 2021, 41(5): 498-500.
- Diagnosis and Treatment Protocol for Novel Coronavirus infection (Trial version 10)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019SK4004-06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Function
-
VA Office of Research and DevelopmentUnited States Department of Defense; Harvard UniversityEnrolling by invitation
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Preventive Services and Health Promotion Research NetworkCompleted
-
University of UtahWithdrawnPulmonary FunctionUnited States
-
Assiut UniversityCompletedPulmonary FunctionEgypt
-
Icahn School of Medicine at Mount SinaiColumbia University; Kintampo Health Research Centre, GhanaCompletedPulmonary Function | Oxidant ImbalanceGhana
-
Boston Children's HospitalWithdrawnInadequate; Pulmonary Function, Newborn
-
Karolinska InstitutetCompletedPulmonary Function | Ventilator Lung | Gas ExchangeSweden
-
China Medical University HospitalRecruitingQi-Xu; Qi Deficiency | Pulmonary Function; COPDTaiwan
-
Centre Hospitalier Universitaire, AmiensRecruitingCardiac Surgery | Postoperative Pulmonary Complications | Ultrasound-guided Parasternal Block | Pulmonary Function TestingFrance
Clinical Trials on Acupuncture
-
Federal University of São PauloCompleted
-
University of ZurichCharite University, Berlin, Germany; First Teaching Hospital of Tianjin University...CompletedExperimental Dental PainSwitzerland
-
University of SkövdeCompleted
-
National Research Centre of Complementary and Alternative...Norwegian Acupuncture CollegeUnknown
-
Chengdu University of Traditional Chinese MedicineChongqing Medical University; Hunan University of Traditional Chinese MedicineCompletedFunctional Dyspepsia | Postprandial Distress SyndromeChina
-
Chang Gung Memorial HospitalRecruitingIntracranial HemorrhagesTaiwan
-
University Medicine GreifswaldRecruitingGagging During Transesophageal EchocardiographyGermany
-
University of MichiganMassachusetts General Hospital; National Center for Complementary and Integrative...Completed
-
Huazhong University of Science and TechnologyThe University of Hong Kong; Heilongjiang University of Chinese Medicine; Hubei...CompletedPolycystic Ovary SyndromeChina
-
China Medical University HospitalNot yet recruiting